

DETECTION WINDOWS

A drug's detection window is the range of time that a drug remains measurable in a biological sample. Detection windows can be helpful in further assessment of a patient; however, the evaluator needs to be aware of detection window limitations. Detection windows generally provide a ballpark average and should be used in combination with the patient's entire clinical picture to ensure accurate evaluation. Many factors, not limited to dose, frequency of use (acute vs chronic), route of administration, biological matrix collected from the patient, cut off levels, and individual metabolic and renal clearance affect drug metabolism and thus affect detection windows.¹⁻⁴

A patient that is prescribed a medication daily, multiple times a day, or has a history of substance use may have lengthened detection windows compared to a single, one-time user.⁴ This is especially true for lipophilic (fat-storing) drugs such as THC, benzodiazepines, and cocaine.^{4,5} Oral, sublingual, and intranasal administration may provide lengthened detection in the oral fluid cavity, whereas transdermal patches may be difficult to capture in the oral cavity but have an increased detection time in urine.^{3,4}

Urine is best suited for detecting parent drug and metabolite(s), while the oral fluid is generally better suited for detecting the parent drug.¹⁻⁴ Oral fluid detection times on average are 1 or 2 days while urine detections times on average are approximately 1.5 to 4 days.⁴ This difference between the two matrices is heavily influenced by the 10-50-fold lower concentration of most drugs in oral fluid.^{2,4} Precision Diagnostics offers Precision NextGen cut off levels in urine, many of which are lower than what is typically seen industrywide; such cut offs can attribute to widening detection windows.⁶

The detection windows of a drug and its metabolite are affected by metabolic and renal clearance of the individual, related to genetic and non-genetic host factors, and in some cases polypharmacy.^{7,8} The major cause of individual variation of drug clearance is due to genetic variation, involving genetic polymorphisms of drug-metabolizing enzymes.⁷ This genetic variation results in subpopulations that differ in drug metabolism.^{7,8}

In addition to genetic variations, non-genetic factors such as sex, age, and disease among populations also give rise to variations in drug clearance.⁸ Lastly, metabolic and renal clearance can greatly be affected by polypharmacy in which drug metabolizing enzymes are inhibited due to the consumption of interacting drugs.⁸

Precision Diagnostics offers a list of average detection windows pertaining to the urine and oral fluid tests we offer. You can also find these detection windows listed on individual patient reports. The data is based on documented scientific literature.

**A Precision Diagnostics trained Clinical Support Specialist can
assist with further review of your patient's results**

(800) 635-6901 Option 2

References:

1. Clinical Drug Testing in Primary Care. U.S. Department of Health and Human Service. 2012, 1-96. <https://store.samhsa.gov/shin/content/SMA12-4668/SMA12-4668.pdf>
2. Langman, L. J., Jannetto, P. J. (2018). Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. The National Academy of Clinical Biochemistry, 1-109.
3. Allen, Keith R. (2011) Screening for drugs of abuse: which matrix, oral fluid or urine. Annals Clinical Biochemistry, 48, 531-541.
4. Verstraete, Allen G. (2004) Detection times of drugs of abuse in blood, urine, and oral fluid. Therapeutic Drug Monitoring, 26, 200-205.
5. Niedbala R. S., Kardos, K. W., Fritch, D. F., Kardo, S., Fries, T., Waga, J. (2001) Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. Journal of Analytical Toxicology, 25: 289-303.
6. Krock, K., Pesce, A., Ritz, D., Thomas, R., Cua, A., Rogers, R., et. al. (2017) Lower cutoffs for LC-MS/MS urine drug testing indicates better patient compliance. Pain Physician, 20: 1107-1113.
7. Meyer, U. A., Zanger, U. M. (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annual Review of Pharmacology and Toxicology, 37: 269-96.
8. Zanger, U. M., Schwab, M. (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression activities, and impact genetic variation. Pharmacology & Therapeutics, 138: 103-141.

Precision Diagnostics, a leader in clinical laboratory testing and medication adherence monitoring, is transforming healthcare through the delivery of comprehensive, insightful clinical data that can help improve patient outcomes and manage costs. Specializing in providing quantitative drug testing, Precision Diagnostics' innovative state-of-the art technology provides insurers, pharmacies, medical practitioners, and patients with new levels of visibility and transparency that allows doctors to better assess patients' medication adherence, ensure patient compliance, and improve outcomes.

Precision Diagnostics

4215 Sorrento Valley Blvd.
San Diego, CA 92121
(800) 635-6901
info@precisiondxlab.com
precisiondxlab.com



innovation



integrity



insights



outcomes